Oxford Immunotec Reports First Quarter 2014 Financial Results
GlobeNewswire - Tue May 06, 6:06AM CDT
-- 2014 First Quarter Revenue of $12.3 Million Increased 60% Compared to Prior Year
Oxford Immunotec Schedules First Quarter 2014 Earnings Release and Conference Call for May 6, 2014
GlobeNewswire - Thu Apr 24, 12:04PM CDT
Oxford Immunotec Global PLC (Nasdaq:OXFD) today announced that it plans to release first quarter 2014 financial results prior to market open on Tuesday, May 6, 2014. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will host a conference call to review the Company's results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast.
Oxford Immunotec receives 2014 Queen's Award for Enterprise
GlobeNewswire - Mon Apr 21, 4:00AM CDT
Oxford Immunotec Global PLC (Nasdaq:OXFD) today announced that it has received a Queen's Award for Enterprise - the UK's highest accolade in business success.
Oxford Immunotec Reports Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Tue Mar 04, 6:11AM CST
-- Fourth Quarter Revenues of $10.2 Million Increased 94% Compared to Prior Year Period
Oxford Immunotec : Schedules Fourth Quarter and Full Year 2013 Earnings Release and Conference Call for March 4, 2014
Thomson Reuters ONE - Mon Feb 24, 1:05PM CST
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 24, 2014 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) today announced that it plans to release fourth quarter and full year 2013 financial results prior to market open on Tuesday, March 4, 2014. Dr. Peter Wrighton-Smith, Chief Executive Officer and Rick Altieri, Chief Financial Officer will host a conference call to review the Company's results at 8:00am Eastern Time the same day. The call will be concurrently webcast.
Dr. Peter Wrighton-Smith Named UK BioIndustry Association (BIA) Entrepreneur of the Year
GlobeNewswire - Fri Jan 31, 5:00AM CST
Oxford Immunotec Global PLC (Nasdaq:OXFD) announced today that its CEO, Dr. Peter Wrighton-Smith has been named the UK BioIndustry Association Entrepreneur of the Year.
Oxford Immunotec Announces Preliminary Fourth Quarter and Fiscal 2013 Revenue and Initiates 2014 Fiscal Year Guidance
GlobeNewswire - Mon Jan 13, 5:00AM CST
-- Preliminary fourth quarter revenue of between $10.1 and $10.5 million, an increase of 91% to 99% over the prior year
Oxford Immunotec to Present at the 32nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Wed Jan 08, 12:08PM CST
Oxford Immunotec Global PLC (Nasdaq:OXFD) today announced that Peter Wrighton-Smith Ph.D., Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will present at the 32 Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco, California on Thursday, January 16, 2014 at 12:30 pm PT.
Upcoming Presentations, Milestone Payments, Quarterly Financial Results, and New Appointments - Research Report on Medivation, Acceleron, Aerie, Arrowhead, and Oxford Immunotec
PR Newswire - Wed Dec 25, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Medivation, Inc. (NASDAQ: MDVN), Acceleron Pharma, Inc. (NASDAQ: XLRN), Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), Arrowhead Research Corp. (NASDAQ: ARWR), and Oxford Immunotec Global PLC (NASDAQ: OXFD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Why Mattress Firm, Navios Maritime Holdings, and Oxford Immunotec Global Soared Today
Dan Caplinger, The Motley Fool - Motley Fool - Thu Dec 05, 7:01PM CST
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis. For the stock market, a fifth straight day of losses for the...
Oxford Immunotec Global PLC Announces Appointment of Herm Rosenman to the Board of Directors
Business Wire - Mon Dec 02, 11:47AM CST
Oxford Immunotec Global PLC (NASDAQ: OXFD) (the "Company"
Oxford Immunotec Global PLC Announces Closing of Initial Public Offering and Exercise of Over-Allotment Option
Business Wire - Mon Dec 02, 11:46AM CST
Oxford Immunotec Global PLC (NASDAQ: OXFD) today announced the closing of its initial public offering of 6,164,000 ordinary shares at an initial public offering price of $12.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 804,000 additional ordinary shares. Oxford estimates net proceeds from the offering to be approximately $62.8 million after deducting underwriting discounts and commissions and estimated offering expenses. The ordinary shares are listed on The NASDAQ Global Market under the trading symbol "OXFD."
Oxford Immunotec Global PLC Announces Pricing of Initial Public Offering
Business Wire - Fri Nov 22, 7:47AM CST
Oxford Immunotec Global PLC (NASDAQ: OXFD) (the "Company"